1 / 45

South Dakota STD Update Webinar – August 15, 2012

South Dakota STD Update Webinar – August 15, 2012. Kees Rietmeijer, MD, PhD Medical Director, Denver STD/HIV Prevention Training Center. A Man with a Faint Rash. The 5-Minute STI Clinical Case Study. Case History. 30 year-old gay man complaining of a faint, non-itching rash for >4 weeks

bruis
Download Presentation

South Dakota STD Update Webinar – August 15, 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. South Dakota STD UpdateWebinar – August 15, 2012 Kees Rietmeijer, MD, PhD Medical Director, Denver STD/HIV Prevention Training Center

  2. A Man with a Faint Rash The 5-Minute STI Clinical Case Study

  3. Case History • 30 year-old gay man complaining of a faint, non-itching rash for >4 weeks • Took left-over amoxicillin for sore throat about 1 month ago – however, pt. does not have a prior history of penicillin allergy • No neurological symptoms or other physical complaints

  4. Case History -Continued • Sexual and STI History • 2 partners in past 6 months: • One steady partner • One occasional partner (about 3 months ago) • Protected receptive and insertive anal sex with steady partner only • Unprotected oral sex with steady and occasional partners • No history of genital/rectal sores • Rectal gonorrhea and chlamydia > 1 year ago • History of primary syphilis – treated 4 years ago with 2.4 MU LAB • Most recent RPR: NR (14 months ago; this clinic • HIV: negative (14 months ago; this clinic)

  5. Physical Exam • Faint erythematous macular rash trunk and extremities • Soles of feet involved, but palms of hands are not • No excoriations or scratch marks noted • No penile or anal lesions observed • Neurological exam: normal

  6. Question 1 What laboratory test would be the least useful in this case? • Qualitative (stat) RPR • Quantitative RPR • Treponemal test (TPPA or FTA-abs) • HIV rapid test • HIV viral load

  7. Stat Lab Results • Qualitative RPR reactive: ++++ • HIV Rapid Test: Positive

  8. Question 2 Based on our knowledge so far, what is the most likely diagnosis? • Acute HIV Infection • Drug rash • Secondary syphilis • Scabies

  9. Question 3 You decide to treat the patient for secondary syphilis – what do the CDC treatment guidelines recommend: • LAB 2.4 MU i.m. now and refer to HIV care • LAB 2.4 MU i.m. now and once a week for 2 subsequent weeks + refer to HIV care • Patient should undergo LP before treatment is initiated • Refer to HIV care as treatment will depend on HIV viral load and CD4 count

  10. Question 4 Regarding the patient’s follow up – which is a CDC recommendation? • Patient should return for follow-up at 1 and 2 weeks for additional treatment • Serological follow-up should be more frequent than in HIV negative patients • Follow-up should include a neurological work-up and LP to exclude neurosyphilis

  11. Gonorrhea The Continuing Saga

  12. Gonorrhea—Rates, United States, 1941–2010 Rate (per 100,000 population) 500 400 300 200 100 0 1941 1946 1951 1956 1961 1966 1971 1976 1981 1986 1991 1996 2001 2006 Year

  13. Gonorrhea—Rates by State, United States and Outlying Areas, 2010 NOTE: The total rate of gonorrhea for the United States and outlying areas (Guam, Puerto Rico, and Virgin Islands) was 99.6 per 100,000 population.

  14. Gonorrhea—Percentage of Reported Cases by Sex and Selected Reporting Sources, United States, 2010 Percentage 35 Private Physician/HMO* STD Clinic 30 Other HD* Clinic Family Planning Clinic 25 Emergency Room 20 15 10 5 0 Men Women * HMO = health maintenance organization; HD = health department. NOTE: These categories represent 69.5% of cases with known reporting source. Of all cases, 13.2% had a missing or unknown reporting source.

  15. Gonococcal Isolate Surveillance Project (GISP)—Penicillin, Tetracycline, and Ciprofloxacin Resistance Among GISP Isolates, 2010 6.9% 2.0% 0.6% 1.8% 2.9% Susceptible 9.4% PenR TetR 3.5% QRNG 72.8% PenR/TetR PenR/QRNG TetR/QRNG PenR/TetR/QRNG NOTE: PenR = penicillinase producing Neisseriagonorrhoeaeand chromosomally mediated penicillin-resistant N. gonorrhoeae; TetR = chromosomally and plasmid mediated tetracycline-resistant N. gonorrhoeae; and QRNG = quinolone-resistant N. gonorrhoeae.

  16. Ceftriaxone 250 mg IM in a single dose OR, IF NOT AN OPTION Cefixime 400 mg orally in a single dose or 400 mg by suspension (200 mg/5ml) PLUS Azithromycin 1g orally in a single dose Or Doxycycline 100 mg twice a day for 7 days Uncomplicated Gonococcal Infections of the Cervix, Urethra, and Rectum CDC 2010 STD Treatment Guidelines

  17. Recommended RegimensCeftriaxone 250 mg IM in a single dose PLUS Azithromycin 1g orally in a single dose Or Doxycycline 100 mg twice a day for 7 days Uncomplicated Gonococcal Infections of the Pharynx CDC 2010 STD Treatment Guidelines

  18. Alternative regimens for uncomplicated gonorrhea Cefpodoxime 400 mg – poor cure rates for pharyngeal infections Cefuroxime 1 g orally – poor cure rates for pharyngeal infections Spectinomycin: no longer available in U.S. Azithromycin 2 g orally – concerns about macrolide resistance Alternative Regimens CDC 2010 STD Treatment Guidelines

  19. Gonococcal Isolate Surveillance Project (GISP)—Drugs Used to Treat Gonorrhea Among GISP Participants, 1988–2010 Percentage 100 Other Tetracyclines Penicillins Ofloxacin 80 Ciprofloxacin 60 Cefixime Ceftriaxone 250 mg 40 20 Spectinomycin Ceftriaxone 125 mg Other Cephalosporins 0 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 Year NOTE: For 2010, “Other” includes no therapy (1.2%), azithromycin 2 g (1.7%), and other less frequently used drugs.

  20. Gonorrhea Isolates with Cefixime MICS >0.25μg/mL MMWR 2011;60:873-877 and MMWR 2012;61:590-594

  21. MMWR 2012;61:590-594

  22. CDC Recommendations for Gonorrhea Treatment - February 2012 • Treat with most effective regimen • Ceftriaxone 250 mg + Azithromycin 1 g • Closely monitor treatment failure • Persistent symptoms: • Test by culture • Submit isolate for resistance testing • MSM: • Consider test of cure after 1 week (by culture or NAAT) especially if treated with cefixime • Report suspected treatment failure Dear Colleague Letter, Dr. Gail Bolan, February 12, 2012

  23. MMWR August 10, 212 • “CDC no longer recommends cefixime at any dose as a first-line regimen for treatment of gonococcal infections.” • “If Cefixime is used as an alternative agent, then the patient should return in 1 week for a test-of-cure at the site of infection.”

  24. MMWR August 10, 2012 • Recommended regimen • Ceftriaxone 250 mg in a single i.m. dose PLUS • Azithromycin 1 g orally in a single dose or • Doxycycline 100 mg orally twice a day for 7 days

  25. MMWR August 10, 2012 • Alternative regimen (if ceftriaxone is not available) • Cefixime 400 mg in a single dose PLUS • Azithromycin 1 g orally in a single dose or • Doxycycline 100 mg orally twice a day for 7 days • Alternative regimen (severe cephalosporin allergy) • Azithromycin 2 g in a single oral dose PLUS with both of the above: • Test-of-cure in 1 week • NAAT • Culture ( preferred if failure is suspected)

  26. Expedited Partner Therapy

  27. Expedited Partner Therapy • Approach whereby partners are treated without an intervening clinical assessment • Patients delivering medications to partners • Patients delivering prescriptions to partners • Field treatment by DIS or outreach workers (with or without testing)

  28. EPT Studies • Schillinger et al. Sex Transm Dis 2003;30:49-56 • 20% reduction in CT re-infection of 20% among women (P = 0.102) • Golden et al. New Engl J Med 2005;352:676-85 • 73% reduction in GC re-infection among men and women (P < 0.01) • 17% reduction in CT re-infection (P = 0.17) • Kissinger et al. Clin Infect Dis 2005; 41:623-9 • 46% reduction in GC and/or CT infection among men with urethritis (P<0.001)

  29. EPT and the STD Treatment Guidelines • “….patient delivered therapy (i.e., via medications or prescriptions) can prevent re-infection of index case and has been associated with a higher likelihood of partner notification, compared with unassisted patient referral of partners” • EPT recommendations are limited to GC and CT contacts only • EPT is not recommended for MSM CDC 2010 STD Treatment Guidelines

  30. EPT Medications • Contact to gonorrhea • Cefixime 400 mg PO x 1 • Azithromycin 1 g PO x 1 • Contact to chlamydia • Azithromycin 1 g PO x 1

  31. Partner Pack Chlamydia

  32. Legal Status of EPT

  33. EPT Acceptance DMHC 2006 - 2009 Mickiewicz et al. Sex Transm Dis 2012; In Press

  34. In the context of decreasing cefixime susceptibility, is it still safe to provide EPT for gonorrhea?

  35. What is the Future for EPT for Gonorrhea? • No recommendations have been made thus far (August 2012 MMWR does not address EPT) • While cefixime susceptibility appears to be decreasing, frank resistance has not (yet) been reported in the U.S. • There are important differences in cefixime susceptibility by region and by sexual preference • Probably safe to continue EPT for gonorrhea among heterosexuals while monitoring susceptibility and resistance regionally • Convey message to patients with gonorrhea that the best option for their partners is to see a health care provider

  36. Gonorrhea The Continuing Saga is….. …well…. Continuing…… Stay Tuned!!!

More Related